Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group.

Vivek M Shastri Lata Chauhan Mohammed Gbadamosi Todd A Alonzo Yi-Cheng Wang Richard Aplenc Betsy A Hirsch Edward Anders Kolb Alan S Gamis Soheil Meshinchi Jatinder Kaur Lamba

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Our results suggest that DDR pathway-based pharmacogenomic score holds potential to predict outcome in patients treated with GO which consists of DNA damaging cytotoxin, calicheamicin. The potential clinical relevance for this score to personalize GO in AML requires further validation in independent and expanded cohorts.

Keyphrases

dna damage response
acute myeloid leukemia
acute lymphoblastic leukemia
young adults
allogeneic hematopoietic stem cell transplantation
human health
circulating tumor
single molecule
clinical decision support
electronic health record